PT  - JOURNAL ARTICLE
AU  - Busby, George B.
AU  - Craig, Paul
AU  - Yousfi, Nesrine
AU  - Hebbalkar, Saurabh
AU  - Di Domenico, Paolo
AU  - Bottà, Giordano
TI  - Genetic assessments of breast cancer risk that do not account for polygenic background are incomplete and lead to incorrect preventative strategies
AID  - 10.1101/2021.08.13.21262050
DP  - 2021 Jan 01
TA  - medRxiv
PG  - 2021.08.13.21262050
4099  - http://medrxiv.org/content/early/2021/08/23/2021.08.13.21262050.short
4100  - http://medrxiv.org/content/early/2021/08/23/2021.08.13.21262050.full
AB  - Breast cancer is the most common cancer among women and is a leading cause of cancer mortality worldwide. There is a significant genetic component to breast cancer risk which is the result of both rare pathogenic mutations and common genome-wide variation. However, the penetrance of pathogenic mutations varies widely and their frequency is low, both at a population level and amongst breast cancer cases. Polygenic risk scores, which aggregate the effect of hundreds to millions of common genome-wide variants offer a way to further understand the contribution of genetics to disease risk. Here we analyse genome-wide data from 221,479 women and 90,307 high coverage exomes to understand how rare and common variation affect lifetime breast cancer risk. We show that PRS strongly modulates the penetrance of mutations in 8 breast cancer susceptibility genes. For example, lifetime risk in BRCA1 carriers with low polygenic risk is almost one third that of carriers with high PRS (26% v 69% in the bottom and top PRS deciles, respectively). Adding family history of breast cancer provides additional stratification on the potential outcome of disease in carriers of rare mutations. PRS also identifies a significant fraction of the population at equivalent risk to carriers of moderate impact pathogenic variants and who are an order of magnitude more common at a population level. These results have important implications for breast cancer risk mitigation strategies, indicating that the genetic risk of breast cancer is determined by both monogenic mutation and polygenic background, and that assessments of genetic risk for breast cancer risk that do not consider the polygenic background are imprecise and unreliable.Competing Interest StatementAll authors are employees of Allelica Inc. GB, GBB, PD own stock in Allelica Inc.Funding StatementThis work was supported by internal reasearch and development funding from Allelica Inc.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:UK Biobank received ethical approval from the North West Multi-Center Research Ethics Committee (11/NW/03820).All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThis work uses data from the UK Biobank which is available to researchers via application. https://www.ukbiobank.ac.uk/